Regeneron – Page 4

FDA Delays Dupixent Decision for COPD by Three Months, EMA Recommends Approval

1 year ago talkbio0Tagged Boreas, Chronic Obstructive Airway Disease, Dupixent, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Notus, PDUFA, Phase 3 Clinical Trials, Priority Review, Regeneron, sanofi, United States Food and Drug Administration

FDA, Dupixent, COPD, EMA, Regeneron, Sanofi, Priority Review, PDUFA, Boreas, Notus, Phase III Trials

FDA Grants Approval for First Interchangeable Biosimilars to Regeneron’s Eylea

1 year ago talkbio0Tagged Approved, Biosimilars, blockbuster, Diabetic Retinopathy, interchangeable, Macular degeneration, Regeneron, Retinal Vein Occlusion, United States Food and Drug Administration

FDA, biosimilars, interchangeable, Regeneron, Eylea, approval, blockbuster, drug, treatment, eye diseases, macular degeneration, diabetic retinopathy, retinal vein occlusion

Regeneron Pharmaceuticals Expands Gene Editing Capabilities with Mammoth Biosciences Partnership

1 year ago talkbio0Tagged Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, development aspects, Gene Modification, Genetic Research, Health care facility, Mammoth Biosciences, Partnership, Regeneron

Regeneron, Mammoth Biosciences, gene editing, CRISPR, partnership, biotechnology, healthcare, pharmaceuticals, genetic research, therapeutic development.